Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids

Archives of Dermatology

Volumn 132, Issue 12, 1996, Pages 1435-1439

  Werth, Victoria P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE SODIUM SUCCINATE;

ACANTHOLYSIS; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; DESMOSOME; DRUG EFFICACY; FEMALE; HUMAN; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MALE; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; REMISSION; STEROID THERAPY; TREATMENT OUTCOME;

EID: 0030460116     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.132.12.1435     Document Type: Article

References (40)

1. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67:869-877.
2. Lever WF, White H. Treatment of pemphigus with corticosteroids. Arch Dermatol. 1963;87:52-66.
3. Sanders SL, Brodey M, Nelson CT. Corticosteroid treatment of pemphigus: experience with fifty cases over a period of ten years. Arch Dermatol. 1960;82:717-724.
4. Lever WF. Pemphigus and pemphigoid: a review of the advances made since 1964. J Am Acad Dermatol. 1979;1:2-31.
5. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris. Arch Dermatol. 1977;113:1236-1241.
6. Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens, Int J Dermatol. 1990;29:363-367.
7. Bystryn J-C. Therapy of pemphigus. Semin Dermatol 1988;7:186-194.
8. Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin. 1993; 11:429-452.
9. Burton JL, Shuster S. Large doses of glucocorticoid in the treatment of alopecia areata. Acts Derm Venereol Suppl (Stockh). 1975;55:493-496.
10. Johnson RB, Lazarus GS. Pulse therapy: therapeutic efficacy in the treatment of pyoderma gangrenosum. Arch Dermatol. 1982;118:76-84.
11. Prystowsky JH, Kahn SN, Lazarus GS. Present status of pyoderma gangrenosum: review of 21 cases. Arch Dermatol. 1989;125:57-64.
12. Pinto GM, Cabecas MA, Riscado M, Goncalves H. Pyoderma gangrenosum associated with systemic lupus erythematosus: response to pulse steroid therapy. J Am Acad Dermatol. 1991;24:818-821.
13. Resnik BI, Rendon M, Kerdel FA. Successful treatment of aggressive pyoderma gangrenosum with pulse steroids and chlorambucil. J Am Acad Dermatol. 1992;27:635-636.
14. Siegel J, Eaglstein WH. High-dose methylprednisolone in the treatment of bullous pemphigoid. Arch Dermatol. 1984;120:1157-1165.
15. Murakami S. Epidermolysis bullosa acquisita in identical twins. J Dermatol. 1991;18:230-234.
16. Dahl MV, Swanson DL, Jacob HS. A dermatitis-eosinophilia syndrome: treatment with methylprednisolone pulse therapy. Arch Dermatol. 1984;120:1595-1597.
17. Snyder RA, Schwartz RA, Schneider JS, Elias PM. Intermittent megadose corticosteroid therapy for generalized lichen planus. J Am Acad Dermatol. 1982;6:1089-1090.
18. Sherertz EF, Jegasothy BV, Lazarus GS. Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. J Am Acad Dermatol. 1985;12:178-181.
19. Case JD, Smith SZ, Callen JP. The use of pulse methylprednisolone and chlorambucil in the treatment of Sweet's syndrome. Cutis. 1989;44:125-129.
20. Goldberg JW, Lidsky MD. Pulse methylprednisolone therapy for persistent sub-acute cutaneous lupus. Arthritis Rheum. 1984;27:837-838.
21. Pandhi RK, Vaswani N, Ramam M, Singh MK, Bhutani LK. Multicentric reticulohistiocytosis: response to dexamethasone pulse therapy. Arch Dermatol. 1990; 126:251-252.
22. Blauvelt A, Kerdel FA. Intravenous corticosteroids for systemic mastocytosis. Arch Dermatol. 1991;127:1586.
23. Werth VP. Management and treatment with systemic glucocorticoids. Adv Dermatol. 1993;8:81-101.
24. Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol. 1976;112:962-970.
25. Krain LS. Pemphigus: epidemiologic and survival characteristics of 59 patients, 1959-1973. Arch Dermatol. 1974;110:862-865.
26. Savin JA. The events leading to the death in patients with pemphigus and pemphigoid. Br J Dermatol. 1979;101:521-534.
27. Ahmed AR, Moy R. Death in pemphigus. J Am Acad Dermatol. 1982;7:221-228.
28. Kanwar AJ, Dhar S. Factors responsible for death in patients with pemphigus. J Dermatol. 1994;92:655-659.
29. Singer KH, Hashimoto K, Jensen PJ, Morioka S, Lazarus GS. Pathogenesis of autoimmunity in pemphigus. Annu Rev Immunol. 1985;3:87-108.
30. Wouters EA, DeClerk LS, Francx L, Stevens WJ. D-penicillamine-induced pemphigus treated with methylprednisolone pulse therapy. Acta Clin Belg. 1990;45:15-19.
31. Chryssomallis F, Dimitriades A, Chaidemenos GC, Panaglotides O, Karakatsanis G. Steroid-pulse therapy in pemphigus vulgaris long-term follow-up, Int J Dermatol. 1995;34:438-442.
32. Fine JD, Appell ML, Green LK, Sams WM Jr. Pemphigus vulgaris: combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine. Arch Dermatol. 1988;124:236-239.
33. Pasricha JS, Das SS. Curative effect of dexamethasone-cyclophosphamide pulse therapy for the treatment of pemphigus vulgaris. Int J Dermatol. 1992;31:875-877.
34. Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus, Int J Dermatol. 1990;29:371-374.
35. Gantz SA. Primer of Biostatistics. New York, NY: McGraw-Hill Book Co; 1992.
36. Haim S, Friedman-birnbaum R. Dapsone in the treatment of pemphigus vulgaris. Dermatologica. 1978;156:120-123.
37. Jablonska S, Chorzelski T. When and how to use sulfones in bullous diseases. Int J Dermatol. 1981;20:103-105.
38. Bystryn J-C. Adjuvant therapy of pemphigus. Arch Dermatol. 1984;120:941-951.
39. Hall ED. The neuroprotective pharmacology of methylprednisolone. J Neurosurg. 1992;76:13-22.
40. White KP, Driscoll MS, Rothe MJ, Grant-Kels JM. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? J Am Acad Dermatol. 1994;30:768-773.